ASRT
Assertio Holdings, Inc. NASDAQ Listed Dec 3, 1997$22.41
Mkt Cap $144.4M
52w Low $8.61
99.4% of range
52w High $22.50
50d MA $16.24
200d MA $12.84
P/E (TTM)
-3.9x
EV/EBITDA
6.8x
P/B
1.3x
Debt/Equity
0.4x
ROE
-32.3%
P/FCF
-2.1x
RSI (14)
—
ATR (14)
—
Beta
0.43
50d MA
$16.24
200d MA
$12.84
Avg Volume
141.6K
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
100 South Saunders Road · Lake Forest, IL 60045 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -3.05 | -1.86 | +39.0% | 11.77 | +2.7% | +6.2% | +16.2% | +16.6% | +13.6% | +18.9% | — |
| Nov 10, 2025 | AMC | -1.20 | 1.65 | +237.5% | 12.02 | -1.7% | +14.8% | +7.9% | +2.9% | -1.2% | -6.4% | — |
| Aug 11, 2025 | AMC | -0.10 | -0.17 | -70.0% | 10.88 | +3.4% | +13.8% | +11.9% | +12.8% | +12.1% | +11.8% | — |
| May 12, 2025 | AMC | -0.06 | -0.14 | -133.3% | 9.23 | -1.0% | -1.1% | -0.5% | +3.9% | +8.2% | +15.5% | — |
| Mar 12, 2025 | AMC | -0.05 | -0.11 | -120.0% | 11.68 | -3.7% | -7.4% | -7.3% | -6.3% | -7.8% | -8.8% | — |
| Nov 11, 2024 | AMC | -0.05 | -0.03 | +40.0% | 13.88 | +1.1% | -7.9% | -7.3% | -9.0% | -12.3% | -9.0% | — |
| Aug 7, 2024 | AMC | -0.03 | -0.04 | -25.0% | 18.45 | +1.6% | -11.4% | -10.6% | -13.0% | -9.8% | -13.0% | — |
| May 6, 2024 | AMC | 0.12 | 0.04 | -66.7% | 18.30 | -3.3% | -9.0% | -13.1% | -13.9% | -21.3% | -13.9% | — |
| Mar 11, 2024 | AMC | -0.00 | 0.11 | +2950.8% | 14.02 | +7.0% | +8.1% | +22.0% | +16.6% | +19.8% | +11.3% | — |
| Nov 8, 2023 | AMC | 0.14 | 0.01 | -92.9% | 31.95 | -45.5% | -43.2% | -47.4% | -51.2% | -49.8% | -46.5% | — |
| Aug 3, 2023 | AMC | 0.14 | 0.13 | -7.1% | 80.25 | -43.9% | -45.6% | -35.7% | -40.4% | -38.9% | -41.7% | — |
| May 9, 2023 | AMC | 0.13 | -0.07 | -153.8% | 104.70 | +0.7% | +8.2% | +9.7% | +9.6% | +4.9% | -2.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Lake Street | Downgrade | Buy → Hold | — | $18.41 | $18.05 | -2.0% | -2.1% | -2.1% | -2.1% | -2.1% | -2.1% |
| Apr 9 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $18.41 | $18.05 | -2.0% | -2.1% | -2.1% | -2.1% | -2.1% | -2.1% |
| Jan 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.14 | $9.26 | +1.3% | +5.4% | +4.3% | +3.2% | +1.9% | +0.5% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.88 | $11.25 | +3.4% | +13.8% | +11.9% | +12.8% | +12.1% | +11.8% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.99 | $10.05 | +0.6% | +6.7% | +3.0% | +3.0% | +6.6% | +5.6% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.77 | $10.95 | +1.7% | -1.1% | -0.9% | +0.7% | +5.4% | +7.0% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.80 | $13.95 | +1.1% | +2.2% | +0.6% | -5.8% | -8.3% | -3.7% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.11 | $14.15 | +0.3% | +7.4% | +4.1% | +3.9% | +6.3% | +8.4% |
| Mar 12 | Lake Street | Maintains | Buy → Buy | — | $14.02 | $15.00 | +7.0% | +8.1% | +22.0% | +16.6% | +19.8% | +11.3% |
| Nov 3 | BWS Financial | Maintains | Buy → Buy | — | $31.95 | $32.85 | +2.8% | +9.9% | +3.8% | +4.2% | +0.0% | -43.2% |
| Aug 4 | BWS Financial | Maintains | Buy → Buy | — | $80.25 | $45.00 | -43.9% | -45.6% | -35.7% | -40.4% | -38.9% | -41.7% |
| May 10 | BWS Financial | Maintains | Buy → Buy | — | $104.70 | $105.45 | +0.7% | +8.2% | +9.7% | +9.6% | +4.9% | -2.4% |
| May 10 | Lake Street | Maintains | Buy → Buy | — | $104.70 | $105.45 | +0.7% | +8.2% | +9.7% | +9.6% | +4.9% | -2.4% |
| Mar 3 | BWS Financial | Maintains | Buy → Buy | — | $86.25 | $87.60 | +1.6% | +8.0% | +6.3% | +7.3% | +3.7% | +15.8% |
| Nov 7 | Lake Street | Maintains | Buy → Buy | — | $40.50 | $42.00 | +3.7% | -0.7% | -3.0% | -1.1% | +3.7% | +9.6% |
| May 18 | BWS Financial | Maintains | Buy → Buy | — | $44.25 | $44.25 | +0.0% | -0.7% | +6.1% | +6.8% | +4.7% | -1.7% |
| Apr 9 | Gabelli & Co. | Upgrade | Hold → Buy | — | $35.40 | $37.20 | +5.1% | +3.4% | -6.8% | -11.9% | -11.9% | -10.2% |
| Nov 25 | Brookline Capital | Maintains | Buy → Buy | — | $25.20 | $25.80 | +2.4% | +2.4% | -2.4% | +0.0% | -2.4% | +0.0% |
| Jun 3 | Brookline Capital | Maintains | Buy → Buy | — | $59.40 | $63.60 | +7.1% | +9.1% | +1.0% | +1.0% | +4.0% | +2.0% |
| Nov 30 | Mizuho | Maintains | Neutral → Neutral | — | $312.60 | $300.00 | -4.0% | -4.2% | -7.1% | -8.6% | -13.6% | -18.0% |
| Aug 29 | Janney Capital | Downgrade | Buy → Neutral | — | $439.20 | $366.60 | -16.5% | -10.9% | -10.5% | -12.8% | -13.9% | -10.8% |
| Jul 9 | Janney Capital | Upgrade | Neutral → Buy | — | $419.40 | $420.00 | +0.1% | +19.3% | +17.3% | +19.6% | +18.0% | +17.5% |
| Dec 5 | Mizuho | Upgrade | Neutral → Buy | — | $429.00 | $483.00 | +12.6% | +9.9% | +13.4% | +16.5% | +14.3% | +16.2% |
| Nov 10 | UBS | Maintains | Neutral → Neutral | — | $355.20 | $354.00 | -0.3% | +8.4% | +8.4% | +2.4% | +3.0% | +4.9% |
| Aug 8 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $553.80 | $438.60 | -20.8% | -33.4% | -34.8% | -32.2% | -31.5% | -33.6% |
| Aug 8 | Janney Capital | Downgrade | Buy → Neutral | — | $553.80 | $438.60 | -20.8% | -33.4% | -34.8% | -32.2% | -31.5% | -33.6% |
| May 10 | PiperJaffray | Upgrade | Underweight → Neutral | — | $657.60 | $573.00 | -12.9% | +1.1% | +6.1% | +7.7% | +7.3% | +2.1% |
| Feb 14 | Mizuho | Downgrade | Buy → Neutral | — | $1020.00 | $986.40 | -3.3% | -1.9% | -1.5% | -0.9% | -3.1% | -7.2% |
| Dec 12 | PiperJaffray | Downgrade | Neutral → Underweight | — | $1212.00 | $1143.00 | -5.7% | -10.2% | -7.6% | -9.1% | -9.1% | -8.1% |
| Nov 9 | Mizuho | Upgrade | Neutral → Buy | — | $1140.60 | $1170.60 | +2.6% | +3.9% | +7.7% | +9.6% | +13.0% | +12.9% |
| Nov 8 | Cantor Fitzgerald | Downgrade | Buy → Hold | — | $1373.40 | $1152.60 | -16.1% | -17.0% | -13.7% | -10.6% | -9.0% | -6.2% |
| Oct 4 | Mizuho Securities | Downgrade | Buy → Neutral | — | $1534.80 | $1503.00 | -2.1% | -0.9% | +1.7% | -0.4% | -1.5% | +0.7% |
| Oct 3 | UBS | Maintains | Neutral → Neutral | — | $1498.20 | $1530.00 | +2.1% | +2.4% | +1.6% | +4.2% | +2.0% | +0.9% |
| Aug 4 | JMP Securities | Maintains | Market Outperform → Outperform | — | $1172.40 | $1149.00 | -2.0% | +4.0% | +8.3% | +8.6% | +10.0% | +8.1% |
| Jul 27 | PiperJaffray | Downgrade | Overweight → Neutral | — | $1144.20 | $1117.20 | -2.4% | -1.9% | +0.9% | -0.5% | +1.3% | +1.0% |
| Jul 7 | UBS | Downgrade | Buy → Neutral | — | $1233.00 | $1195.20 | -3.1% | -8.7% | -8.7% | -7.4% | -7.3% | -9.7% |
| May 9 | Mizuho | Upgrade | Neutral → Buy | — | $930.60 | $997.80 | +7.2% | +15.1% | +17.5% | +14.3% | +13.0% | +15.2% |
| Mar 24 | Northland Securities | Maintains | Outperform → Outperform | — | $788.40 | $776.40 | -1.5% | +1.3% | -0.7% | +5.3% | +5.7% | +6.0% |
| Mar 10 | Leerink Swann | Maintains | Outperform → Outperform | — | $877.20 | $900.60 | +2.7% | +3.9% | +10.9% | +11.1% | -2.1% | -3.0% |
| Feb 9 | UBS | Maintains | Buy → Buy | — | $913.20 | $913.20 | +0.0% | +3.9% | +1.6% | +5.6% | +5.6% | +8.3% |
| Jan 7 | Mizuho | Maintains | Neutral → Neutral | — | $1035.60 | $1000.80 | -3.4% | -7.1% | -10.5% | -14.6% | -12.7% | -18.5% |
| Nov 12 | Roth Capital | Maintains | Buy → Buy | — | $1194.00 | $1191.60 | -0.2% | -1.1% | -6.1% | -2.6% | -3.9% | -0.5% |
| Nov 11 | Wallachbeth | Upgrade | Hold → Buy | — | $1272.60 | $1198.80 | -5.8% | -6.2% | -7.2% | -11.9% | -8.6% | -9.9% |
| Nov 4 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $1138.20 | $1146.60 | +0.7% | +0.4% | -3.6% | +4.7% | +6.0% | +11.8% |
| Jul 30 | RBC Capital | Downgrade | Outperform → Perform | — | $1912.20 | $1918.20 | +0.3% | -4.2% | -1.2% | -2.2% | -3.4% | -3.2% |
| Jul 30 | Janney Capital | Downgrade | Buy → Neutral | — | $1912.20 | $1918.20 | +0.3% | -4.2% | -1.2% | -2.2% | -3.4% | -3.2% |
| Jun 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $1271.40 | $1278.00 | +0.5% | +1.3% | -2.1% | -1.8% | +0.4% | +0.4% |
| Jun 10 | Janney Capital | Maintains | Buy → Buy | — | $1288.80 | $1291.80 | +0.2% | -1.4% | -0.0% | -3.4% | -3.1% | -0.9% |
| May 12 | Janney Capital | Upgrade | Neutral → Buy | — | $1464.60 | $1303.80 | -11.0% | -16.3% | -18.5% | -18.0% | -15.9% | -17.2% |
| Apr 22 | PiperJaffray | Maintains | Overweight → Overweight | — | $1589.40 | $1600.20 | +0.7% | +2.5% | +3.0% | +4.4% | -2.7% | -5.2% |
No insider trades available.
8-K · 5.02
!!! Very High
Assertio Holdings, Inc. -- 8-K 5.02: Executive Change
May 7
8-K · 7.01
! Medium
Assertio Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Assertio Holdings disclosed material non-public information via press release filing, though the specific disclosure content requires reviewing the attached exhibit for investor impact assessment.
May 5
8-K · 1.01
!!! Very High
Assertio Holdings, Inc. -- 8-K 1.01: Merger Agreement
Assertio Holdings agreed to merge with Garda Therapeutics under an amended merger agreement, potentially consolidating the two pharmaceutical companies and reshaping Assertio's corporate structure.
May 4
8-K · 7.01
! Medium
Assertio Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Assertio Holdings disclosed material information through a press release filing, though the specific details aren't provided in this summary, so investors should review Exhibit 99.1 for the announcement's impact on ASRT.
Apr 29
8-K · 7.01
! Medium
Assertio Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Garda plans to launch a tender offer for all outstanding Assertio Holdings shares on April 29, 2026, following completion of the required regulatory review period under their merger agreement.
Apr 21
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
Assertio divested its core therapeutic business to a litigation-focused acquirer, potentially signaling a pivot toward legacy litigation monetization rather than drug development, which fundamentally changes the company's business model and risk profile.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
ASRT's CEO agreed to amended restrictive covenants tied to the merger, likely signaling management continuity post-acquisition but potentially restricting his future employment opportunities and warranting investor scrutiny of deal terms.
Apr 9
8-K · 1.01
!!! Very High
Unknown — 8-K 1.01: Merger Agreement
ASRT likely faces significant dilution or loss of independence as it pursues a merger with Garda Therapeutics, requiring investors to reassess their position based on deal terms and valuation.
Apr 9
8-K
Unknown — 8-K Filing
Assertio beat FY2025 guidance and projects modest 2026 growth ($110-125M sales), signaling operational stability but limited expansion—investors should assess whether the narrow guidance range reflects confidence or maturing market headwinds.
Mar 16
8-K
Sensei Biotherapeutics, Inc. -- 8-K Filing
Sensei Biotherapeutics appointed a new CFO with significant biotech finance experience, including prior roles at Jaguar Gene Therapy and board positions at Tectonic Therapeutic, strengthening leadership capabilities.
Feb 13
Data updated apr 24, 2026 7:19pm
· Source: massive.com